why choose us

300×250 Ad Slot

Research Article: Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML

Date Published: 2023-06-13

Introduction:
Acute myeloid leukemia (AML) is predominantly a disease of the elderly, with a median age of at diagnosis. , Advanced age, high frequency of unfavorable genomic features and less favorable clinical characteristics, including reduced biological function and more complex medical comorbidities, may contribute to the inability of older patients to tolerate high-dose chemotherapy. , Also, refractory/relapsed (R/R) AML is associated with a poor prognosis. The treatment outcome for R/R AML patients are rather poor and…

Read more

300×250 Ad Slot